120 related articles for article (PubMed ID: 1330970)
1. Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer.
Rosell R; Carles J; Abad A; Ribelles N; Barnadas A; Benavides A; Martin M
Invest New Drugs; 1992 Aug; 10(3):171-5. PubMed ID: 1330970
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of mitonafide in non-small cell lung cancer (NSCLC).
Casado A; Rosell R; García-Gómez R; Díaz-Rubio E; Pérez-Manga G; Font A; Benavides A; Martín M
Invest New Drugs; 1996; 14(4):415-7. PubMed ID: 9157079
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of mitonafide in solid tumors.
Llombart M; Poveda A; Forner E; Fernández-Martos C; Gaspar C; Muñoz M; Olmos T; Ruiz A; Soriano V; Benavides A
Invest New Drugs; 1992 Aug; 10(3):177-81. PubMed ID: 1428727
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity.
Díaz-Rubio E; Martín M; López-Vega JM; Casado A; Benavides A
Invest New Drugs; 1994; 12(4):277-81. PubMed ID: 7775127
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of Mitonafide in advanced and relapsed colorectal cancer.
Abad A; Grávalos C; Font A; Molina F; Díaz-Puente MT; Fabregat X; Benavides A; Martín M
Invest New Drugs; 1996; 14(2):223-5. PubMed ID: 8913845
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical investigation of amonafide.
Saez R; Craig JB; Kuhn JG; Weiss GR; Koeller J; Phillips J; Havlin K; Harman G; Hardy J; Melink TJ
J Clin Oncol; 1989 Sep; 7(9):1351-8. PubMed ID: 2549205
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.
Berger MZ; Kris MG; Gralla RJ; Marks LD; Potanovich LM; Dimaggio JJ; Heelan RT
Am J Clin Oncol; 1991 Apr; 14(2):124-6. PubMed ID: 1851387
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group.
Gesme DH; Jett JR; Schreffler DD; Su JQ; Mailliard JA; Foley JF; Krook JE; Maksymiuk AW; Hatfield AK; Ebbert LP
Cancer; 1993 May; 71(9):2723-6. PubMed ID: 8385564
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of amonafide in advanced and recurrent sarcoma patients.
Perez RP; Nash SL; Ozols RF; Comis RL; O'Dwyer PJ
Invest New Drugs; 1992 Jul; 10(2):99-101. PubMed ID: 1500272
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of amonafide in advanced breast cancer.
Scheithauer W; Dittrich C; Kornek G; Haider K; Linkesch W; Gisslinger H; Depisch D
Breast Cancer Res Treat; 1991 Dec; 20(1):63-7. PubMed ID: 1813070
[TBL] [Abstract][Full Text] [Related]
11. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic characterization of mitonafide in man.
Brode E; Poveda Velasco A; Díaz-Rubio E; Rosell Costa R; Benavides Fissure A
Methods Find Exp Clin Pharmacol; 1992 Mar; 14(2):131-40. PubMed ID: 1598025
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588).
Chang AY; Tu ZN; Smith JL; Bonomi P; Smith TJ; Wiernik PH; Blum R
Invest New Drugs; 1995; 13(2):137-41. PubMed ID: 8617576
[TBL] [Abstract][Full Text] [Related]
14. Phase I-II trial of concomitant continuous carboplatin (CBDCA) infusion and radiotherapy in advanced nonsmall cell lung cancer with evaluation for surgery: final report.
Trodella L; Cellini N; Picciocchi A; Marano P; Balducci M; Mantini G; Turriziani A; Corbo GM; Valente S; Valentini V; Pirronti T; Granone P; Dobelbower RR
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):93-101. PubMed ID: 9054882
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study.
Hanson KH; Crowley J; Salmon SE; Keppen M; Braun TJ; Bonnet JD
Anticancer Drugs; 1991 Jun; 2(3):247-50. PubMed ID: 1802018
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.
Hainsworth JD; Thompson DS; Greco FA
J Clin Oncol; 1995 Jul; 13(7):1609-14. PubMed ID: 7602349
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.
Evans WK; Eisenhauer EA; Cormier Y; Ayoub J; Wierzbicki R; Laberge F; Shepherd FA
J Clin Oncol; 1990 Mar; 8(3):390-5. PubMed ID: 2155309
[TBL] [Abstract][Full Text] [Related]
19. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Ratain MJ; Mick R; Janisch L; Berezin F; Schilsky RL; Vogelzang NJ; Kut M
Pharmacogenetics; 1996 Feb; 6(1):93-101. PubMed ID: 8845865
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
